Skip to content
10-K

Annual Report

Marker Therapeutics, Inc. MRKR

0001104659-26-031274

← back to feed
Filed
Mar 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 16.67M sh
Shares Diluted FY 2025 · Dec 31, 2025 15.31M sh
Shares Diluted FY 2025 · Dec 31, 2024 8.98M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$12.01M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$10.91M
Cash And Equivalents FY 2025 · Dec 31, 2025 $16.07M
Cash And Equivalents FY 2025 · Dec 31, 2024 $19.19M
Stockholders Equity FY 2025 · Dec 31, 2025 $16.8M
Stockholders Equity FY 2025 · Dec 31, 2024 $18.56M
Stockholders Equity FY 2025 · Dec 31, 2023 $14.05M
Current Liabilities FY 2025 · Dec 31, 2025 $2.27M
Current Liabilities FY 2025 · Dec 31, 2024 $3.46M
Total Liabilities FY 2025 · Dec 31, 2025 $2.27M
Total Liabilities FY 2025 · Dec 31, 2024 $3.46M
Current Assets FY 2025 · Dec 31, 2025 $19.07M
Current Assets FY 2025 · Dec 31, 2024 $22.02M
Total Assets FY 2025 · Dec 31, 2025 $19.07M
Total Assets FY 2025 · Dec 31, 2024 $22.02M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.79
Eps Diluted FY 2025 · Dec 31, 2024 −$1.19
Eps Basic FY 2025 · Dec 31, 2025 −$0.79
Eps Basic FY 2025 · Dec 31, 2024 −$1.19
Sga Expense FY 2025 · Dec 31, 2025 $4.18M
Sga Expense FY 2025 · Dec 31, 2024 $4.24M
Rd Expense FY 2025 · Dec 31, 2025 $11.8M
Rd Expense FY 2025 · Dec 31, 2024 $13.47M
Net Income FY 2025 · Dec 31, 2025 −$12.16M
Net Income FY 2025 · Dec 31, 2024 −$10.73M
Operating Income FY 2025 · Dec 31, 2025 −$12.89M
Operating Income FY 2025 · Dec 31, 2024 −$11.12M